Neuland Sees FY26 Growth Beat, But Cash Flow Still Negative

Neuland Laboratories Limited — Q4 & FY26 Earnings Call (Quarter & Year ended Mar 31, 2026; call held May 12, 2026)

1. Overall Tone of Management: Optimistic

• Management highlights “record-breaking Q4” and says FY26 growth outlook was “accurate” and “slightly better than expected.”
• They emphasize “strong degree of confidence over the next few years” and “outlook… remains promising,” while repeatedly framing variability as inherent and manageable.

2. Key Themes from Management Commentary

• Strong FY26 growth led by CMS/CDMO: FY26 revenue INR 2,053.1 cr (+37.1% YoY); Q4 CMS contributed “over two thirds of revenue.”
• Margin strength attributed to mix + one-off factors: Q4 gross margin 62.1% and EBITDA margin 40.5%, but management stresses it “should not be seen as an indicator of our future performance” (uneven/lumpy revenue + exchange rate + freight).
• Cash conversion remains a key constraint: FY26 free cash flow negative (INR -49.4 cr); working capital days rose to 137 days (inventories + receivables), with expectation to “normalize in FY27.”
• Cost/process discipline as structural lever: initiatives to improve productivity, procurement efficiency, standardization, and tighter controls to “protect margins” and improve cash generation.
• Visibility anchored in commercial/near-commercial molecules: “business visibility continues to be anchored by commercial and near commercial molecules.”
• Peptide strategy as the next growth engine: investment in large-scale peptide commercial facilities and a “new R&D center” to enable earlier engagement and larger programs.
• Capital allocation shifting to longer cycles: ROCE expected to “moderate as we enter longer capital deployment cycles,” but management is comfortable if it strengthens the growth engine.
• Risk framing is consistent: demand variability, regulatory timelines, geopolitical/supply chain volatility, and execution risk for longer programs.

3. Q&A Analysis

Theme A: Drivers of CDMO/CMS growth & shipment lumpiness

• Core questions
• What drove CDMO/CMS growth in Q4 (currency vs underlying volume/molecules vs order bunching)?
• Any new commercial products added vs ramp-up of existing ones?
• Management response
• Currency helped: “shipments happened as the rupee depreciated,” but growth also reflects “products we’ve been looking at in our pipeline.”
• One new commercialization in FY26; growth mainly from “ramp-up of volumes of previously commercialized products.”
• Volatility is “based on shipments” and “nothing out of the ordinary.”
• Assessment
• Generally direct; however, they avoid quantifying the split between currency/volume/order timing.

Theme B: Peptide CDMO contract value, timing, and client pitch

• Core questions
• For an announced peptide contract: what value-add now, and how contracts work if programs move to later stages?
• What is Neuland’s “selling point” for peptide clients and how does LIR Life Sciences help?
• Management response
• Contract is “very early-stage”; they “would not really associate any near or mid-term revenue.”
• They cite 8–10 peptide programs in development; commercialization likely “at least a few years.”
• Pitch: “16, 18 years” in peptides; in-house process development (process chemistry, not medicinal chemistry) and now building manufacturing infrastructure.
• Assessment
• Strongly conservative on near-term revenue; provides rationale but keeps commercial economics opaque.

Theme C: Modality positioning (peptides vs ADCs/oligos) and manufacturing bottlenecks

• Core questions
• Capability gaps vs hybrid modalities (ADCs, fermentation-enabled manufacturing).
• What is the real bottleneck for emerging biotech routes vs synthetic chemistry?
• Management response
• They partially disagree with the premise: peptides are “as or more attractive” than oligos; ADCs are a “future adjacency.”
• Bottleneck answer: synthetic chemistry is “far higher scale and more reliable”; biotech processes are harder on yield/purification/contamination/regulatory.
• Assessment
• Clear strategic narrative; some confidence is opinionated (“more compelling today”) rather than evidenced with metrics.

Theme D: Customer M&A / bempedoic acid transaction implications

• Core questions
• Does Esperion’s acquisition/bid change outlook for bempedoic acid post-patent expiry?
• Any messaging from the transaction?
• Management response
• Confidentiality: cannot comment on specific molecules.
• General view: sponsor M&A is “natural part of the business”; supply agreements typically have clauses; customers prioritize “continuity.”
• They reiterate short/medium-term growth visibility and say they would temper outlook only if short-term challenges emerge.
• Assessment
• Reasonable, but still deflects the investor’s core concern (post-expiry risk) to generalities.

Theme E: Guidance philosophy, growth/margin trajectory, and modeling approach

• Core questions
• Can investors rely on past quantitative guidance (e.g., 18–20% CAGR)?
• Should margins be modeled using H2 vs Q4?
• Management response
• “18% to 20% is a fair assumption” (not necessarily linear).
• They won’t provide H2/Q4 split: “I don’t know off top of my head… I don’t want to comment.”
• Margins: they claim conservatism in budgeting; “things are looking slightly better” than their typical picture; “nothing has changed fundamentally.”
• Assessment
• Provides a usable CAGR anchor but avoids concrete margin guidance; relies on “trend line” rather than numbers.

Theme F: Capacity utilization & capex cycle explanation

• Core questions
• Current capacity utilization across units.
• What does “longer capital deployment cycle” mean for capex and cash utilization?
• Management response
• Utilization: “85% to 90%” for three units; last unit “around 65%.”
• Capex mindset shift: from tactical investments tied to secured contracts to longer-term preparedness for scaling (bigger revenue base implies “hundreds of crores every year” growth).
• Assessment
• More concrete on utilization; still vague on capex quantum for FY27/FY28.

Theme G: Governance / transcript integrity concern (inventory manipulation allegation)

• Core questions
• An investor alleged transcript editing changed essence of a prior Q3 question on inventory manipulation; asked for justification.
• Management response
• CFO: “I’ll have to check… revert back” (no immediate rebuttal).
• They ask which quarter; promise to check.
• Assessment
• This is a credibility risk: no denial, no immediate clarification.

4. Guidance / Outlook

Explicit guidance (quantitative)

• No formal revenue/margin guidance given.
• CAGR anchor (qualitative-to-quantitative): “18% to 20% is a fair assumption” (not linear).
• Capacity utilization: 85–90% (three units), ~65% (one unit).
• Peptide facility timeline: “facility will be ready by July” (no change in date).

Implicit signals (qualitative)

• Growth visibility: anchored by “commercial and near commercial molecules” with “strong degree of confidence over the next few years.”
• FY27 working capital normalization: working capital days “should normalize in FY27.”
• Margin outlook: FY26 margin strength partly FX/mix; ROCE expected to “moderate” with longer capex cycles.
• Peptide monetization timing: early-stage contracts; “not… near or mid-term revenue”; commercialization “at least a few years.”
• Volatility persists: management says lumpy growth likely continues; investors should model over “10 to 12 quarters.”

5. Standout Statements (direct / high-signal)

• On Q4 margin sustainability: “This exceptional operating margin… should not be seen as an indicator of our future performance.”
• On visibility: “business visibility continues to be anchored by commercial and near commercial molecules.”
• On peptide contract revenue timing: “very early-stage program” and “would not really associate any near or mid-term revenue.”
• On working capital normalization: working capital days “should normalize in FY27.”
• On capex/returns tradeoff: “ROCE… is expected to moderate as we enter longer capital deployment cycles.”
• On CAGR: “18% to 20% is a fair assumption… not necessarily linearly.”
• On volatility modeling: “assessed over a longer horizon… 10 to 12 quarters, a clear trend line should emerge.”
• On transcript integrity allegation: CFO did not refute; “I’ll have to check… and revert back.”

6. Red Flags / Positive Signals

Red flags
– Credibility / governance risk: inventory manipulation transcript allegation met with “check and revert” rather than immediate clarification.
– Cash conversion deterioration: FY26 FCF negative and working capital days up to 137; normalization only expected in FY27 (timing risk).
– Margin narrative hedged: repeated emphasis that Q4 margin is not indicative; suggests earnings quality may be mix/FX-driven.
– Confidentiality limits investor visibility: multiple questions on specific molecules (bempedoic acid, peptide contract) deflected to generalities.

Positive signals
– Operational execution confidence: ramp-up and shipments described as on track; peptide facility “ready by July.”
– Capacity utilization disclosed: 85–90% for most units indicates productive use of assets.
– Strategic clarity: consistent long-term plan—commercial/near-commercial base + peptide scaling + R&D capability build.

7. Historical Comparison & Consistency Analysis (vs prior 3 calls)

a. Change in Tone Over Time

• Q1 FY26 (Jul 31, 2025): “performance has been below par,” but confident FY26 growth would resume; still cautious.
• Q2 FY26 (Nov 7, 2025): “numbers… substantiate our earlier expectations,” optimistic; margins strong.
• Q3 FY26 (Feb 9, 2026): “in line with our expectations,” but working capital deterioration and product mix issues acknowledged.
• Q4 & FY26 (May 12, 2026): tone becomes more optimistic: “record-breaking Q4,” FY26 outlook “accurate,” “slightly better than expected.”
• Shift classification: More Optimistic.
• More confidence in near-term direction; less emphasis on “below par” framing.
• Still hedges margins and cash conversion, but overall sentiment improved.

b. Tracking Past Commitments vs Outcomes

• Peptide facility readiness (earlier calls):
• Past statement (Nov 7, 2025): new peptide facility “completed in the next financial year.”
• Current outcome (May 12, 2026): “facility will be ready by July as per schedule.”
• Flag: ✅ Delivered (at least on timing).
• Unit 3 / CMS ramp-up and commercialization milestones:
• Past statement (Feb 9, 2026): ramp-up “started,” expected “another one or two quarters” to pick up; additional CMS molecule commercialization shipments tail end Q3/Q4.
• Current (May 12, 2026): Q4 record performance; management attributes growth to existing pipeline + ramp-ups; one new commercialization in FY26.
• Flag: ✅ Delivered (directionally), though they still attribute growth partly to FX and shipment timing.
• Working capital normalization expectation:
• Past (Feb 9, 2026): working capital deterioration acknowledged; actions to optimize collections/inventory.
• Current (May 12, 2026): working capital days rose further to 137; normalization only expected in FY27.
• Flag: ⏳ Delayed (not achieved by FY26 end).

c. Narrative Shifts

• From “FY26 growth recovery” to “record execution + long-term engine”:
• Earlier calls focused on ramp-up and “below par” quarters (Q1).
• Now narrative emphasizes long-term growth visibility and peptide investment as foundational.
• Margins narrative becomes more defensive:
• Q2/Q3 had margin explanations tied to mix and operating leverage.
• Q4 introduces stronger caveat: exceptional margins “should not be seen” as future indicator.
• Peptide monetization expectations remain consistently conservative:
• Even after facility progress, management continues to say contracts are early-stage and not near-term revenue.

d. Consistency & Credibility Signals

• Credibility: Medium
• Consistent theme: business is lumpy; evaluate over longer horizons.
• Consistent strategic direction: CMS base + peptide scaling + R&D capability.
• However, cash conversion worsened and margin sustainability is repeatedly caveated, which can reduce confidence in earnings quality.
• The transcript integrity/inventory manipulation allegation is a notable credibility stressor.

e. Evolution of Key Themes

• Demand/visibility: Improving/stable—visibility anchored in commercial/near-commercial molecules.
• Margins: Volatile—Q4 shows peak margins but management warns it’s not repeatable.
• Cash conversion: Deteriorating in FY26 (FCF negative; working capital up), with only FY27 normalization expectation.
• Expansion/capex: Moving from tactical to longer-cycle planning; ROCE moderation expected.

f. Additional Insights (cross-period intelligence)

• Earnings quality risk is increasing: as margins peak (Q4 EBITDA margin 40.5%), management simultaneously highlights uneven revenue and FX/freight effects—suggesting investors should separate “performance optics” from sustainable run-rate.
• Cash discipline remains the main execution gap: despite strong revenue growth, FCF stayed negative and working capital days increased—this is the clearest operational mismatch vs the growth narrative.
• Peptide strategy is progressing on schedule, but monetization remains distant: facility readiness is advancing, yet revenue contribution is repeatedly pushed out (“few years”), implying near-term upside is still mainly from CMS ramp-ups.